Axovant Sciences (AXON) Sinks as Lundbeck 5-HT6 antagonist Fails
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Axovant Sciences (NYSE: AXON) weakens on news Lundbeck 5-HT6 antagonist fails in Alzheimer's Phase III. Adam Feuerstein notes on Twitter that AXON also has a 5-HT6 antagonist.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Corbus Pharma (CRBP) Mentioned Cautiously by Adam Feuerstein
- Varian Medical Systems (VAR) CFO Finney to Retire
- ARIAD Pharma (ARIA) Announces Publication of Brigatinib Preclinical Data in NSCLC
Create E-mail Alert Related CategoriesFDA, Trader Talk
Related EntitiesTwitter, Adam Feuerstein
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!